›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Archer™ VARIANTPlex™ Complete Solid Tumor panel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Integrated DNA TechnologiesType:
Laboratory Developed Test
Related tests:
Archer™ VARIANTPlex™ Complete Solid Tumor panel detect single nucleotide variants, copy number variations, insertions and deletions in 430 genes along with microsatellite instability, tumor mutational burden, and homologous recombination deficiency status with targeted NGS relevant for colorectal, breast, melanoma, gastric, pancreatic, CNS, NSCLC and other pan-cancer research.
Cancer:
Breast Cancer, CNS Tumor, Colorectal Cancer, Gastric Cancer, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDK4 (Cyclin-dependent kinase 4)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDK4 (Cyclin-dependent kinase 4), CDK6 (Cyclin-dependent kinase 6), EGFR (Epidermal growth factor receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), ERBB4 (erb-b2 receptor tyrosine kinase 4), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FOXA2 (Forkhead Box A2), FOXO1 (Forkhead box O1), FOXP1 (Forkhead Box P1), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MET (MET proto-oncogene, receptor tyrosine kinase), NOTCH1 (Notch 1), NOTCH2 (Notch 2), NOTCH3 (Notch Receptor 3), NOTCH4 (Notch 4), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), POLE (DNA Polymerase Epsilon), PTEN (Phosphatase and tensin homolog), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TP53 (Tumor protein P53), mTOR (Mechanistic target of rapamycin kinase)
Method:
Next-Generation Sequencing (NGS)
